Comparing 15 and 45 Minutes of Blood Flow Clamping During Liver Cancer Surgery
Compares two clamping times during liver surgery for cancer in adults.
Plain-language title generated from the registry record
Registry title: 15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial
Key facts
- Where
- Warsaw, PolandSee the site
Where in Poland
- Department of General, Transplant and Liver Surgery, Medical University of WarsawWarsaw, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Warsaw
- Trial code
- NCT07237204
- Record updated
- 19 November 2025
- Original description
The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors. The main questions it aims to answer are:Read full original descriptionShow less
A Prospective, Randomized Noninferiority Trial Comparing 15- and 45-minute Pringle Maneuvers During Liver Resection for Oncologic Indications.
The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors. The main questions it aims to answer are:
Is the incidence of post-hepatectomy liver failure different between 15-minute and 45-minute Pringle maneuver durations?
* Do the durations differ in operative time or intraoperative blood loss? * Researchers will compare patients randomized 1:1 to 15 minutes vs 45 minutes of Pringle clamping to see if outcomes are non-inferior between groups.
Participants will:
* Undergo standard oncologic hepatectomy with the assigned Pringle duration. * Receive routine perioperative assessments, including laboratory tests and clinical evaluations. * Attend follow-up visits at approximately 6 months, 1 year, and 3 years after surgery.
Inclusion: Diagnosis of a primary or secondary malignant liver tumor; Age > 18 years; Patient deemed eligible for liver resection; WHO performance status ≤ 2; Ability to provide written informed consent.
Exclusion: Prior ablation or chemoembolization of hepatic lesions; Prior portal vein branch embolization; Concomitant resection of any organ other than the gallbladder during the same operation; Liver cirrhosis; Liver dysfunction classified as Child-Pugh class B or C; Repeat hepatectomy; Planned or performed ALPPS procedure.